Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 17/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pterin-6-Carboxylic Acid SCHEMBL17439631 | 0.98 | AKR1B1 (0.55) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL7677720 | 0.88 | AKR1B1 (0.60) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL20781324 | 0.82 | AKR1B1 (0.40) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL20781323 | 0.81 | AKR1B1 (0.41) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL3528804 | 0.76 | MAPK1 (0.41) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL22497884 | 0.76 | ALDH1A1 (0.40) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL853172 | 0.76 | ALDH1A1 (0.40) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL3528784 | 0.76 | ALDH1A1 (0.40) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL3526052 | 0.76 | KDM4E (0.40) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL1981722 | 0.75 | ALDH1A1 (0.41) | AKR1B1ALDH1A1HSD17B10KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119875643-A | Flashing liquid medicine and preparation method and flashing method thereof | 昆山市板明电子科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119145013-A | Nickel electroplating liquid and preparation method and application thereof | 生益电子股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024212361-A1 | USE OF BIOMARKER COMBINATION IN PREPARATION OF LUNG CANCER PREDICTION PRODUCT | 南京品生医学检验实验室有限公司 | 2024-10-17 | — | — | WO | claimed |
| WO-2024212363-A1 | USE OF BIOMARKER COMBINATION IN PREPARATION OF BREAST CANCER PREDICTION PRODUCT | 南京品生医学检验实验室有限公司 | 2024-10-17 | — | — | WO | claimed |
| CN-118408901-A | Rapid detection method for biopterin compounds in environmental water sample | 南京大学 | 2024-07-30 | — | — | CN | claimed |
| CN-117723644-A | Method for detecting water-soluble vitamins, hormones, nucleosides, organic acids and amino acids in biological sample | 南京品生医学检验实验室有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-116106535-B | Application of biomarker combination in preparation of breast cancer prediction product | 南京品生医学检验实验室有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-116106535-A | Application of biomarker combination in preparation of breast cancer prediction product | 南京品生医学检验实验室有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-116106534-A | Application of biomarker combination in preparation of lung cancer prediction product | 南京品生医学检验实验室有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-113125611-B | Method for detecting content of impurity 6-formyl pterin folic acid | 北京斯利安药业有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-20110147217-A1 | METHOD AND APPARATUS FOR CANCER SCREENING | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2011-06-23 | — | — | US | claimed |
| US-20090270397-A1 | Methods and compositions for the treatment of cancers, such as melanomas and gliomas | NEW YORK UNIVERSITY | 2009-10-29 | — | — | US | claimed |
| WO-2009126274-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS, SUCH AS MELANOMAS AND GLIOMAS | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-10-15 | — | — | WO | claimed |
| US-6576105-B1 | Cancer monitoring and screening | TRUMAN STATE UNIVERSITY | 2003-06-10 | — | — | US | claimed |
| US-6358953-B1 | ADMINISTERING PTERIN METAL COMPLEX AS ANTICARCINOGENIC AGENTS AND VIRICIDES | Moheno, Phillip B. B. | 2002-03-19 | — | — | US | claimed |
| EP-1123294-A1 | NOVEL PTERIN ANTINEOPLASTIC AGENTS | Moheno, Phillip B. B. (US) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023448-A1 | NOVEL PTERIN ANTINEOPLASTIC AGENTS | MOHENO PHILLIP B B (US) | 2000-04-27 | — | — | WO | claimed |
| US-5854008-A | Europium and terbium chelators for the time-resolved fluorometric assays | NORDION INTERNATIONAL, INC. (CA) | 1998-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270397-A1 | Methods and compositions for the treatment of cancers, such as melanomas and gliomas | MGMT, FOLR2, DHFR | AKR1B1 1824/4885ALDH1A1 450/4885HSD17B10 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.